Capecitabine and Skin Toxicity in Colorectal Cancer Treatment
Author Information
Author(s): Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass H G, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Giessen C, Moosmann N, Heinemann V
Primary Institution: Medical Department III, University of Munich, Klinikum Muenchen-Grosshadern
Hypothesis
There is a correlation between capecitabine-induced skin toxicity and treatment efficacy in patients with metastatic colorectal cancer.
Conclusion
The study found that capecitabine-induced skin toxicity is associated with better treatment outcomes in terms of disease control rate, progression-free survival, and overall survival.
Supporting Evidence
- Capecitabine-attributed skin toxicity was observed in 32.2% of patients.
- Patients with grade 1-3 skin toxicity had a disease control rate of 97.9% compared to 86.1% for those with grade 0.
- Progression-free survival was significantly longer in patients with grade 1-3 skin toxicity (9.9 months) compared to those with grade 0 (5.6 months).
- Overall survival was also longer for patients with grade 1-3 skin toxicity (32.8 months) compared to grade 0 (22.4 months).
Takeaway
If patients taking capecitabine for cancer treatment get skin rashes, it might mean the treatment is working better for them.
Methodology
Patients were randomized to receive either capecitabine with irinotecan or capecitabine with oxaliplatin, and skin toxicity was evaluated alongside treatment efficacy.
Limitations
The study is limited by its retrospective nature and the relatively small patient number.
Participant Demographics
Patients with metastatic colorectal cancer from 35 German centers.
Statistical Information
P-Value
P=0.038 for disease control rate; P<0.001 for progression-free survival; P=0.008 for overall survival.
Confidence Interval
95% CI: 40.9–64.0 for overall response rate; 95% CI: 4.8–6.3 for progression-free survival.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website